Personalized tumor neoantigen peptide vaccine

drug_type

RELEVANT_DRUG

intervention_type

Biological

drug_description

A patient-specific therapeutic cancer peptide vaccine composed of synthetic peptides representing tumor-specific somatic mutations selected via whole-exome/RNA sequencing and HLA typing to generate high-affinity HLA-binding peptides. Designed to prime and expand neoantigen-specific CD8+ and CD4+ T cells via dendritic cell antigen presentation, enabling recognition and killing of tumor cells expressing the targeted neoantigens.

nci_thesaurus_definition

NCI thesaurus definition not available.

drug_mesh_term

Cancer Vaccines

drug_category

PEPTIDE VACCINE

drug_class

Vaccine

drug_delivery_route

Not specified

drug_mechanism_of_action

Patient-specific synthetic neoantigen peptides are selected by tumor sequencing and HLA typing and administered to be taken up and presented by antigen-presenting cells (HLA class I/II). This primes and expands neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells, enabling immune recognition and killing of tumor cells expressing the targeted mutations.

drug_name

Personalized tumor neoantigen peptide vaccine

nct_id_drug_ref

NCT06314087